The U.S Food and Drug Administration (FDA) plays a critical role in protecting and promoting the health of all Americans. Every day, the FDA does important work to ensure the safety, efficacy and security of our nation’s medical products, including human drugs and biologics. From reviewing the drug profile of a first-in-class medicine up for approval, to inspecting a medicine’s manufacturing site, the FDA’s experts engage in a range of regulatory review activities intended to bring safe and effective new medicines to patients in a timely manner. In the past year alone, the FDA approved a record number of new medicines to fight a range of diseases, including multiple sclerosis, Alzheimer’s disease and Parkinson’s disease.
The FDA is also on the front lines helping to deliver increased personalized medicine access to patients. The agency’s efforts approving new immunotherapy and cell and gene-based therapy treatment options, which harness a patient’s own immune system to defeat a disease, are revolutionizing the treatment paradigm. At the same time, the agency is enhancing a competitive biopharmaceutical marketplace, including approving a record-setting number of generic medicines in 2017.
None of these milestones would have been possible without the dedicated professionals who work at FDA and contribute to the agency being recognized as the gold-standard for the regulatory review of drugs and biologics. I should know: during my time at the FDA as the Deputy Center Director for Science Operations for the Center for Drug Evaluation and Research, I had the privilege of working with these talented professionals who bring to bear their expertise and hard work to fulfill the FDA’s public health oversight mission and ensure the medicines we take are safe and effective for ourselves and our loved ones.
A stable and sustainable workforce is crucial to the FDA’s success in keeping pace with scientific advances in biopharmaceutical drug development and ensuring safe and effective innovative medicines reach patients in a timely manner. However, the FDA has faced significant human resource challenges in recent years, requiring that the agency and the biopharmaceutical industry work together to find solutions to enhance its recruiting and hiring.
Under the sixth authorization of the Prescription Drug User Fee Act (PDUFA VI), the second authorization of the Biosimilar User Fee Act (BsUFA II), and through passage of the 21st Century Cures Act, the FDA has been given additional resources and new hiring and pay authorities to build and maintain the agency’s workforce. These include agency hiring goals and related recruitment and retention initiatives, a hiring pilot intended to modernize and streamline hiring processes, and establishment of a dedicated staffing team charged with the continuous recruiting, staffing, and retention of scientific, technical and professional staff – the biostatisticians, medical reviewers, and project managers, just to name a few - who want to make a difference in the lives of Americans.
America’s biopharmaceutical companies are taking bold steps to develop medicines to treat life-threatening diseases and give hope to patients, providers and caregivers alike, as well as bring value to the health care system. But we can’t do it alone. As we embark on this new era of medicine, the FDA must continue to grow its team of dedicated professionals ready to tackle some of the most complex medical issues of our time. If you are interested in serving, please visit the agency’s hiring page.
Richard Moscicki M D
Dr. Moscicki served as executive vice president, Science and Regulatory Advocacy and chief medical officer at PhRMA from 2017-summer of 2022. He joined the organization after serving as the Deputy Center Director for Science Operations for the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) since 2013. While at FDA, Dr. Moscicki brought executive direction of Center operations and leadership in overseeing the development, implementation, and direction of CDER’s programs. Previous positions include serving as Chief Medical Officer at Genzyme Corporation from 1992 to 2011, where he was responsible for worldwide global regulatory and pharmacovigilance matters, as well as all aspects of clinical research and medical affairs for the company. He served as the senior vice president and head of Clinical Development at Sanofi-Genzyme from 2011-2013.
Richard Moscicki M D
Why PDUFA VIII keeps patients first and strengthens America's biopharma leadership
Mass compounding puts patients at risk
PDUFA creates an efficient drug review process that benefits American patients
Advancing patient care: A look at new medicines approved in 2025
Knockoffs of FDA-approved drugs put patients at risk
PDUFA: Essential to America’s edge in drug development and patient access
Major drug compounder is spending millions on misleading Super Bowl ad
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
More oversight needed of unapproved medicines that threaten patients’ health
The use of real-world data in drug development
New analysis: Accelerated approval pathway is changing lives in underserved communities
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
Florida’s importation plan puts patients in danger
The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings
Decentralized clinical trials and the future of drug development
How FDA’s modernization strategy could improve drug development
Setting the record straight on accelerated approval
FDA should remain the authority on the safety and effectiveness of medicines
Novel medicines approved in 2022 offer increased treatment options for patients
What you should know about real-world evidence and drug development
Three things to know about the accelerated approval pathway
PDUFA and BsUFA reauthorizations are wins for patients
Timely reauthorization of PDUFA and BsUFA is vital to the FDA’s review of medicines
Word of the Month: Biomarkers and surrogate endpoints
Ensuring timely reauthorization of PDUFA and BsUFA
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
The accelerated approval pathway: Helping patients with serious or life-threatening diseases
The importance of timely PDUFA and BsUFA reauthorization
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
World AIDS Day: Remembering those we’ve lost and exploring the continued fight against HIV/AIDS
Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition
Meeting Tomorrow: Looking ahead to PDUFA VII
The impact of monoclonal antibodies and COVID-19 recovery
PDUFA VII is critical for future biopharmaceutical innovation and for patients
3 things that support robust biopharmaceutical research and development
How strengthening the biosimilar marketplace benefits patients
The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Nearly 400 cell and gene therapies in development to target a broad range of diseases
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
Guest Post: Using the patient voice to go boldly
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
Clinical Trials Awareness Week: Celebrating innovation in clinical research
Guest post: Hearing from patients on Rare Disease Day
Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation
Why state drug importation pilot programs don’t work
Putting 2018 medicine approvals in context
Balancing innovation and competition in the biologics marketplace
New analysis shows that more medicines worldwide are available to U.S. patients
Bringing innovation to clinical trial design
Spending on medicines grew less than one percent in 2017
Rare Disease Day: Unmet need inspires innovation
Innovation comes in many forms, including new and expanded uses of existing medicines
ICYMI: Why 2017 medicine approvals matter
New surveys find payers and providers want more data from biopharmaceutical companies
Supporting opportunities for enhanced competition in the marketplace
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
The next five years of PDUFA VI: Driving the availability of innovative treatments for patients
Opportunities to build upon enhanced competition for medicines in the marketplace
Why reauthorization of PDUFA matters
A critical opportunity to prevent prescription drug abuse
Guest Post: The importance of a modern FDA in drug discovery
FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies
FDA
PDUFA
FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies
FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies